A review of new FDA approvals in I/O therapy regarding a nivolumab/ipilimumab-based regimen as seen in the CheckMate 227 and CheckMate 9LA studies, along with considerations for immune-related adverse events.

Data from the following clinical trials are discussed:

CheckMate 227: Nivolumab plus ipilimumab in advanced non–small cell lung cancer (Hellmann MD et al. 

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: Three-year update from CheckMate 227 Part 1. (Ramalingam SS et al. 2020 ASCO annual meeting. Abstract 9500.)

Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line treatment for stage IV/recurrent non–small cell lung cancer: CheckMate 9LA. (Reck M et al. 2020 ASCO annual meeting. Abstract 9501.)

IMpower110: Clinical safety in a phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in first-line non–small cell lung cancer. (Jassem J et al. 2020 ASCO annual meeting. Abstract e21623.)

Videos

Updates on I/O Therapy for Non-Driver mNSCLC

Thoracic oncologists evaluate emerging data presented at the ASCO 2020 virtual meeting on agents for the treatment of 

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with 

exon 20 insertions. (Piotrowska Z et al. 2020 ASCO annual meeting. Abstract 9513.)

Poziotinib shows activity and durability of responses in subgroups of previously treated 

exon 20 NSCLC patients. (Le X at al. 2020 ASCO annual meeting. Abstract 9514.)

Amivantamab (JNJ-61186372), an anti–EGFR-MET bispecific antibody, in patients with 

exon 20 insertion-mutated non–small cell lung cancer. (Park K et al. 2020 ASCO annual meeting. Abstract 9512.)

EGFR Exon 20 Mutations in NSCLC

 mutations and incorporating AMG 510 and MRTX849 into clinical practice when treating mNSCLC.

KRAS-Mutant NSCLC

Detecting HER2 expression by IHC in lung cancer, the role of ADCs in targeting 

mutations, and the FDA breakthrough designation for trastuzumab deruxtecan are examined.

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with 

-mutated metastatic non–small cell lung cancer: Interim results of DESTINY-Lung01. (Smit EF et al. 2020 ASCO annual meeting. Abstract 9504.)

HER2 Targeted Therapy for Treatment of NSCLC

A discussion on the FDA approved treatment option, capmatinib, and FDA breakthrough therapy designation, tepotinib, for treatment of mNSCLC with 

-amplified advanced non–small cell lung cancer: results from cohort 6 of the phase 2 GEOMETRY mono-1 study. (Groen HJM et al. 2020 ASCO annual meeting. Abstract 9520.)

Tepotinib in non–small cell lung cancer with 

exon 14 skipping mutations. (Paik PK et al. 

MET Exon 14 Mutations in mNSCLC

 fusion+ metastatic non–ؘsmall-cell lung cancer and insights on approaching testing for 

Selpercatinib (LOXO-292) in patients with 

-fusion+ non–small cell lung cancer. (Goto K et al. 2020 ASCO annual meeting. Abstract 3584.)

Intracranial activity of selpercatinib (LOXO-292) in 

 fusion-positive non–small cell lung cancer patients on the LIBRETTO-001 trial. (Subbiah V et al. 2020 ASCO annual meeting. Abstract 9516.)

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients with advanced 

 fusion+ non–small cell lung cancer. (Gainor JF et al. 2020 ASCO annual meeting. Abstract 9515.)

Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

Articles

Updates on I/O Therapy for Non-Driver mNSCLC

EGFR Exon 20 Mutations in NSCLC

KRAS-Mutant NSCLC

HER2 Targeted Therapy for Treatment of NSCLC

MET Exon 14 Mutations in mNSCLC

RET Fusion+ mNSCLC

Educational Tools for Possible Drug-Induced ILD

Management of Patients Who Develop ILD

Changes in Treatment Goals due to Drug Induced ILD

Risk of ILD as a Class Effect and Identifying ILD

Risks for Developing ILD in Gastrointestinal Cancer Studies

Role of Antibody Drug Conjugates and Personal Experience

Patient Management and Educational Tools for ILD

Identifying Drug-Induced ILD

Rate of ILD and Monitoring Parameters

Personal Experience with Drug-Induced ILD

Potential Risk of Drug-Induced Interstitial Lung Disease

Patient Management upon Developing ILD and Education

Patient Factors for Developing ILD and Personal Experience

Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials